![Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX]](https://cedclinic.com/wp-content/uploads/2026/06/ced-unsplash-ke6jYtwXDKA-1-150x150.jpg "Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX] 18")
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.
Table of Contents
Clinical Takeaway
Research consistently shows that daily cannabis use, especially when started in adolescence or young adulthood, is associated with higher rates of psychosis, bipolar disorder, anxiety, depression, and suicidal behavior. This relationship holds across multiple types of evidence, including population studies, genetic research, and laboratory findings. Young people who develop cannabis use disorder appear to be at particular risk for these mental health conditions.
#33 Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.
Citation: Hall Wayne et al.. Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.. The lancet. Psychiatry. 2026. PMID: 42309106.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Design: 0 Journal: 4 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Abstract: Cannabis use often begins in adolescence and young adulthood, when anxiety, depression, psychosis, and bipolar disorder typically first develop. Young people aged in their mid-teens to mid-twenties who engage in daily cannabis use and develop a cannabis use disorder have a higher prevalence of these mental disorders. We assessed the coherence of evidence from epidemiological, genetic, experimental, and preclinical studies to assess relationships between daily cannabis use and the increased incidence, prevalence, and persistence of psychosis, bipolar disorder, anxiety, depression, and suicidal behaviours. We found credible evidence that daily cannabis use is a contributory cause of psychosis. There were fewer high quality epidemiological and genetic studies of bipolar disorder. The role of cannabis use in depression, anxiety, and suicidality was less certain because associations were modest and could reflect self-medication, shared risk factors, or bidirectional relationships. A high priority should be given to developing effective interventions for cannabis use disorders in people with mental disorders.
What This Study Teaches Us
Daily cannabis use in adolescents and young adults appears to be a genuine contributory cause of psychosis, not just an association. The evidence for cannabis causing depression, anxiety, or suicidality is weaker and may reflect users self-medicating existing conditions or sharing genetic vulnerabilities with mental illness.
Why This Matters Clinically
If you’re counseling a teenager or young adult about cannabis, you now have a clearer threshold: psychosis risk is real enough to warrant explicit discussion, while depression or anxiety associations are murkier and shouldn’t be used as a blanket scare tactic. For patients already struggling with mental health, the distinction matters for treatment planning.
Study Snapshot
| Study Design | Systematic review assessing coherence across epidemiological, genetic, experimental, and preclinical studies |
| Population | Young people mid-teens to mid-twenties engaging in daily cannabis use, with focus on those developing cannabis use disorder |
| Intervention | Not applicable. Review of existing evidence across multiple study types rather than an intervention study |
| Primary Outcome | Assessment of causal relationships between daily cannabis use and psychosis, bipolar disorder, anxiety, depression, and suicidal behaviors |
| Key Result | Credible evidence for cannabis as a contributory cause of psychosis. Weaker evidence for bipolar disorder. Modest and uncertain associations with depression, anxiety, and suicidality that may reflect self-medication or shared risk factors |
Where This Paper Deserves Skepticism
This is a narrative review synthesizing evidence across very different methodologies, not a meta-analysis with pooled estimates. The abstract doesn’t specify how authors weighted conflicting studies or resolved disagreements, which is critical when coherence across methods is the main claim. The finding that depression and anxiety associations ‘could reflect’ self-medication or confounding acknowledges these mechanisms exist, but the abstract doesn’t quantify how much of the observed association they actually explain. We don’t know the recency or completeness of the literature search.
Dr. Caplan’s Take
I find the psychosis signal credible because it’s supported across study types and the temporal relationship (cannabis use preceding symptom onset) is plausible. What I appreciate about this review is its intellectual honesty about the depression and anxiety question: the authors resist overstating weak evidence. In my practice, I distinguish between ‘cannabis can trigger psychosis in vulnerable people’ (actionable for counseling) and ‘cannabis causes depression’ (less clear, requires individualized assessment). The priority they flag around treating cannabis use disorders in mentally ill populations is where I’d focus clinical energy.
Clinical Bottom Line
Counsel young people frankly about psychosis risk with daily use. For depression and anxiety, the relationship is less certain and bidirectional, so don’t assume cannabis is the culprit without exploring the full clinical picture. Screening for cannabis use disorder in patients with mental illness should be standard.
|
Have thoughts on this? Share it:
